Introduction
============

Alveolar Soft-Part Sarcoma (ASPS) is an extremely rare soft tissue sarcoma of adolescents and young adults ([@ref-15]; [@ref-50]). ASPS usually manifests as a soft, painless, slow-growing mass and although disease follows an indolent course, it has the potential to metastasize to several sites ([@ref-52]). ASPS is characterized by an unbalanced translocation t(X;17)(p11;q25) that fuses the ASPSCR1 and TFE3 genes, generating a fusion protein that drives pathogenesis ([@ref-40]). Evidence suggests that the fusion protein accumulates in the nucleus and directs transcriptional activity ([@ref-2]; [@ref-4]; [@ref-21]). For example, ASPL-TFE3 binds and activates MET transcription, resulting in an overall enhancement in kinase activity in the presence of hepatocyte growth factor ([@ref-69]). As a consequence, some clinical benefit is being achieved with kinase inhibitors targeting MET ([@ref-50]; [@ref-57]).

Despite this progress, the origin of disease is still the subject of intense speculation ([@ref-13]). A longstanding hypothesis posits that ASPS has a myogenous origin ([@ref-12]; [@ref-13]; [@ref-46]). However, ASPS tumors do not appear to express markers of muscle cell differentiation such as the myogenic nuclear regulatory proteins MyoD1 and myogenin ([@ref-16]; [@ref-23]; [@ref-64]; [@ref-72]). Several transcriptomic studies have also been published that speculate on the origin of disease ([@ref-17]; [@ref-58]; [@ref-60]; [@ref-66]). In 2009 we undertook one of the first microarray studies of ASPS and identified expression of several muscle-restricted transcripts (ITGB1BP3/MIBP, MYF5, MYF6, and TRIM63). However, these data were generated using universal RNA as a reference, which may have biased results towards skeletal muscle expressed transcripts ([@ref-60]). [@ref-58] showed that the transcription factor PAX6 was upregulated in primary ASPS, suggesting a "tentative neural line of differentiation for ASPS". [@ref-17] generated microarray data from a mouse model of ASPS and also human patient samples. These authors speculated that "some mesenchymal progenitor, possibly pericyte/endothelial in character, provides one potential cell of origin". Similarly, [@ref-66] were able to model ASPS through ectopic expression of ASPL-TFE3 in murine embryonic, but not adult, mesenchymal cells. These observations underscore the current lack of clarity with respect to ASPS ontogeny and lend support to the suggestion that ASPS cells represent a "scrambled" phenotype where the ASPL-TFE3 fusion impairs differentiation ([@ref-13]; [@ref-47]).

In 2011, a multi-year study culminated in the development of an ASPS cell line designated ASPS-1 ([@ref-31]). This reagent provided the first opportunity to study ASPS gene expression without interference from contaminating cell types. Microarray data was subsequently generated for ASPS-1 as part of the NCI sarcoma cell line panel ([@ref-68]). In the current study, ASPS-1 data was mined relative to the entire NCI sarcoma cell line panel. These efforts were combined with re-analysis of microarray and RNA-seq studies focusing on ASPS patient samples ([@ref-17]; [@ref-37]; [@ref-60]). In this regard, we aimed to unify current publicly available transcriptomic data into a consensus profile that can be used as a basis for exploring disease ontogeny and therapeutic vulnerabilities. Results obtained in this study show that, at the mRNA level, ASPS resembles a mesenchymal stromal cell (MSC).[^1^](#fn-1){ref-type="fn"} [^1]

Materials and Methods
=====================

This study utilized six datasets downloaded from the gene expression omnibus (<https://www.ncbi.nlm.nih.gov/geo/>). [GSE68591](GSE68591) comprises exon expression data (Affymetrix Human Exon 1.0 v2 ST platform) for the NCI sarcoma cell line panel (includes data from ASPS-1, 67 sarcoma lines, and five normal tissues) ([@ref-68]). [GSE13433](GSE13433) comprises mRNA expression data for seven ASPS patient tumors analyzed using the Affymetrix U133 plus 2.0 platform ([@ref-60]). For the analyses of data from [GSE13433](GSE13433), additional U133 plus 2.0 control arrays were obtained from [GSE17070](GSE17070) (normal skeletal muscle) and [GSE118370](GSE118370) (normal lung). [GSE32569](GSE32569) comprises a set of U133 plus 2.0 microarrays generated from six patients pre- and post- treatment with Cediranib ([@ref-37]). Lastly, [GSE54729](GSE54729) comprises RNA-seq data (HiSeq 2000) from five ASPS patients and three skeletal muscle controls. The overall study design is illustrated in [Fig. 1](#fig-1){ref-type="fig"}. For experiments involving Affymetrix human Exon 1.0 ST and U133 plus 2.0 arrays differentially expressed genes were identified using the Transcriptome Analysis Console (TAC 4.0, ThermoFisher Scientific) using standard algorithm and comparison settings (RMA normalization, *P* \< 0.05, FDR \<0.05, fold change +/-2). The TAC was also used to generate hierarchical clusters using the automated workflow. For RNA-seq data, differential expression values relative to skeletal muscle were determined using the [GSE54729](GSE54729)\_10408R.txt spreadsheet that accompanies the submission. In detail, normalized FKPM values were averaged for the 5 human ASPS samples and the 3 normal human skeletal muscles samples; fold changes were then calculated from these values. In terms of utilities; the GTEX portal (<https://www.gtexportal.org/>) multi gene query option (<https://gtexportal.org/home/multiGeneQueryPage>) was used to inform tissue of origin from the top 50 differentially expressed ASPS-1 transcripts. Similarly, the GTEX Top 50 expressed genes search function (<https://gtexportal.org/home/topExpressedGenePage>) was used to identify genes expressed selectively in skeletal muscle. The Protein Atlas (<https://www.proteinatlas.org/>) was used to investigate both mRNA and protein expression in normal and cancerous samples for specific transcripts. The *in silico* surfaceome (<http://wlab.ethz.ch/surfaceome/>) ([@ref-3]) was used to predict the hierarchy of cell surface protein expression for ASPS-1. In detail, a file containing the published human surfaceome (table_S3_surfaceome.xlsx) was downloaded from <http://wlab.ethz.ch/surfaceome/> and merged, using MS excel, with the list of differentially expressed ASPS-1 transcripts. Transcripts appearing in both datasets were then extracted and sorted according to ASPS-1 expression. The VENN diagram utility InteractiVenn (<http://www.interactivenn.net/>) ([@ref-20]) was used to determine the extent of overlap between the 4 different experimental approaches.

![Study design.\
This study focuses on the analysis of four publicly available GEO gene-expression datasets. [GSE68591](GSE68591) comprises exon level expression data for the NCI sarcoma cell line panel, which includes data for the ASPS cell line ASPS-1. The remaining three studies comprise transcriptomic data for ASPS patient samples. [GSE13433](GSE13433) comprises Affymetrix U133 plus 2.0 microarray data from our initial gene expression study of seven ASPS patients. [GSE32569](GSE32569) uses the same array platform to study ASPS patient sample responses to Cedirinib. Lastly, [GSE54729](GSE54729) comprises Illumina HISeq 2000 RNA-seq data for ASPS patient samples generated as part of an ASPS mouse modeling study. These data were re-analyzed using appropriate controls in order to generate a consensus transcriptome and gain insights into ASPS pathobiology.](peerj-08-9394-g001){#fig-1}

Results and Discussion
======================

In the first analysis, ASPS-1 exon-level data from the NCI sarcoma cell line panel was analyzed relative to all samples (cancer and normal). Results shown in [Table 1](#table-1){ref-type="table"} list the top fifty transcripts over-expressed in ASPS-1 relative to the average ([Data S1](#supp-2){ref-type="supplementary-material"}). Results demonstrated that crystallin alpha beta (*CRYAB*) mRNA showed the highest expression in ASPS-1 relative to the average (227 fold). Metallothionein 1G (*MT1G)* was the next most elevated (202 fold). Following this were several lower-abundance transcripts coding for *C7orf69*, Synaptic Vesicle Glycoprotein 2B (*SV2B*) and Germinal Center-Associated Signaling and Motility-Like Protein (*GCSAML*). In common with the initial published report of ASPS-1, results also confirmed expression of GPNMB ([@ref-31]). Likewise, ASPS-1 had some of the highest levels of *MET,* and *VEGFR2* in the panel, both of which are previously noted characteristics of disease ([@ref-29]; [@ref-60]; [@ref-69]). This analysis served to confirm the ASPS origin of ASPS-1 as outlined in [@ref-31].

Following this, ASPS-1 was subjected to hierarchical clustering relative to the entire NCI sarcoma cell line panel ([Fig. 2A](#fig-2){ref-type="fig"}). Results showed that ASPS-1 was an outlier that did not closely align with any lines/tissues in the panel. Those specimens with the nearest similarity are shown in [Fig. 2B](#fig-2){ref-type="fig"}; this includes normal cell/tissues such as knee articular chondrocytes, dermal fibroblasts, skeletal muscle, mesenchymal stem cells and osteoblasts. Cancer line relatives included the spindle cell sarcoma Hs 132.T, the fibrosarcomas Hs 93.T and Hs 414.T along with the chondrosarcoma Hs 819. In order to define which changes were guiding this clustering, several breakout analyses were performed. Over-expressed transcripts found in the nearest cluster group and ASPS-1 included *GPNMB*, *CRYAB*, *FABP3,* and *CTSK,* which are markers of mesenchymal cells ([@ref-9]; [@ref-36]; [@ref-73]; [@ref-74]). Transcripts expressed only in ASPS-1 relative to the nearest cluster included *SEPT3*, *C7orf69*, *MT1G,* and *ACP5,* many of which are implicated in the differentiation of mesenchymal stromal cells ([@ref-10]; [@ref-19]; [@ref-45]; [@ref-65]). Lastly, the nearest cluster group could be distinguished from ASPS-1 through higher expression of the canonical fibroblast markers *GREM1*, *LOX*, *THY1,* and *POSTN* ([@ref-22]; [@ref-27]; [@ref-30]). These data point towards a mesenchymal stromal origin that had not undergone significant fibroblast lineage specialization.
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###### The top fifty over-expressed genes in ASPS-1 relative to the average of the NCI sarcoma cell line panel.

![](peerj-08-9394-g005)

  **Gene symbol**   **Affy ID**   **Description**                                                             **FC ASPS-1 vs. Av**
  ----------------- ------------- --------------------------------------------------------------------------- ----------------------
  CRYAB; FDXACB1    3391149       crystallin alpha B; ferredoxin-fold anticodon binding domain containing 1   227.1
  MT1G              3692999       metallothionein 1G                                                          202.9
  C7orf69           3000905       chromosome 7 open reading frame 69                                          202.0
  GCSAML            2390102       germinal center-associated, signaling and motility-like                     177.6
  SV2B              3608638       synaptic vesicle glycoprotein 2B                                            132.6
  ADGRL4            2419432       adhesion G protein-coupled receptor L4                                      129.9
  PLA2G7            2955827       phospholipase A2, group VII                                                 93.5
  SULT1C2           2498911       sulfotransferase family 1C member 2                                         91.3
  SLN               3389954       sarcolipin                                                                  88.9
  CFAP61            3878972       cilia and flagella associated protein 61                                    85.2
  PPEF1             3970714       protein phosphatase, EF-hand calcium binding domain 1                       82.4
  ACP5              3851072       acid phosphatase 5, tartrate resistant                                      79.8
  CD36              3010503       CD36 molecule (thrombospondin receptor)                                     79.1
  PPARGC1A          2763550       peroxisome proliferator-activated receptor gamma, coactivator 1 alpha       78.9
  ASB11             4000485       ankyrin repeat and SOCS box containing 11, E3 ubiquitin protein ligase      78.1
  BMP5              2958172       bone morphogenetic protein 5                                                74.9
  PRUNE2            3210616       prune homolog 2 (Drosophila)                                                72.3
  SUCNR1            2648098       succinate receptor 1                                                        66.5
  PSG9              3864286       pregnancy specific beta-1-glycoprotein 9                                    66.0
  CKMT2             2818035       creatine kinase, mitochondrial 2 (sarcomeric)                               61.7
  DPP4              2584018       dipeptidyl-peptidase 4                                                      61.2
  ABCB1             3060182       ATP binding cassette subfamily B member 1                                   59.7
  SCIN              2990404       scinderin                                                                   58.7
  FABP3             2404418       fatty acid binding protein 3, muscle and heart                              55.8
  PRUNE2            3210497       prune homolog 2 (Drosophila)                                                55.7
  SLC27A2           3593575       solute carrier family 27 (fatty acid transporter), member 2                 54.7
  SLCO4C1           2869096       solute carrier organic anion transporter family, member 4C1                 51.9
  PSG11,5,4,2       3863929       pregnancy specific beta-1-glycoprotein 11,5,4,2                             50.4
  PRLR              2853102       prolactin receptor                                                          47.9
  NPY6R             2830450       neuropeptide Y receptor Y6 (pseudogene)                                     44.6
  ANXA3             2732844       annexin A3                                                                  43.2
  TRPC7             2876793       transient receptor potential cation channel, subfamily C, member 7          42.9
  CD5L              2439138       CD5 molecule-like                                                           41.0
  AKR1C2            3274758       aldo-keto reductase family 1, member C2                                     40.9
  GPNMB             2992814       glycoprotein (transmembrane) nmb                                            40.3
  IL13RA2           4018729       interleukin 13 receptor, alpha 2                                            39.1
  LRRC39            2425173       leucine rich repeat containing 39                                           38.8
  CST1              3901361       cystatin SN                                                                 37.4
  CDH7              3792273       cadherin 7, type 2                                                          36.8
  DOK5              3889833       docking protein 5                                                           35.1
  SEPT3; WBP2NL     3947227       septin 3; WBP2 N-terminal like                                              34.8
  GCNT3             3596147       glucosaminyl (N-acetyl) transferase 3, mucin type                           34.8
  ENPP5             2955673       ectonucleotide pyrophosphatase/phosphodiesterase 5 (putative)               34.7
  DOK3              2888879       docking protein 3                                                           34.2
  LCP1              3512874       lymphocyte cytosolic protein 1 (L-plastin)                                  34.0
  CDA               2324084       cytidine deaminase                                                          33.4
  KLHL4             3983324       kelch-like family member 4                                                  33.3
  CTSK              2434609       cathepsin K                                                                 31.5
  LIPC              3595691       lipase, hepatic                                                             31.0
  RPSA              3827218       ribosomal protein SA                                                        30.0

![Analysis of ASPS-1 transcriptomic data.\
(A) Heirarchical clustering of the NCI sarcoma cell line panel exon array data (B) tissue or tumor derivation for cluster nearest ASPS-1. (C) GTEX tissue of origin analysis for top fifty ASPS-1 transcripts.](peerj-08-9394-g002){#fig-2}

The Genotype-Tissue Expression (GTEx) portal (<https://www.gtexportal.org/>) was then used in order to determine whether the ASPS-1 expression data suggested a tissue of origin. Results obtained using the top fifty over-expressed transcripts suggested that cardiac/skeletal muscle was a likely origin through expression of transcripts such as *CRYAB*, *FABP3*, *SLN*, and *CKMT2* ([Fig. 2C](#fig-2){ref-type="fig"}). The GTEX database also lists the top 50 transcripts expressed by normal skeletal muscle, where 28 (e.g., creatine kinase M-Type *CKM* and myoglobin *MB*) have a considerable degree of muscle-specificity. Results showed that only two transcripts from this set, *EEF1A2* and *SLN* are over-expressed in ASPS-1. As a consequence, we then undertook an expansive study of whether ASPS-1 had any hallmarks of myogenic differentiation. [Figure 3](#fig-3){ref-type="fig"} plots raw expression data for all cell lines in the sarcoma panel, where lines are grouped according to histology. Results showed that ASPS-1, unlike some rhabdosarcoma lines, did not express myogenic regulatory factor mRNAs including *MYF5*, *MYF6*, *MYOD1*, *MYOG*, and similarly did not express *PAX3* and *PAX7.* Taken together these observations suggest that although ASPS-1 has hallmarks of a muscle resident cell, it had not undergone myogenic differentiation.

![Expression of myogenesis-related transcripts in ASPS-1 relative to the other sarcoma cell lines.\
Cell lines in the NCI sarcoma panel were segregated according to disease type and the average of exon expression data plotted for transcripts encoding myogenesis-related transcription factors and muscle structural proteins. ASPS-1 data is shown first; then RMS, Rhabdomyosarcoma; RT, Rhabdoid tumor; LMS, Leiomyosarcoma; CS, Chondrosarcoma; FS, Fibrosarcoma; EWS, Ewings Sarcoma; OS, Osteosarcoma; SS, Synovial Sarcoma; US, Uterine Sarcoma; SNOS, Sarcoma not otherwise specified; GCS, Giant cell sarcoma; MNS, Malignant peripheral nerve sheath; LPS, Liposarcoma; SPS, Spindle cell sarcoma; EP, Epithelioid; NC, Normal cells; SkMc, skeletal muscle cells. For transcripts; *MYF5*, Myogenic Factor 5, *MYF6*, Myogenic Factor 6, *MYOD1*, Myogenic Differentiation 1, *MYOG* = Myogenin, *PAX3*, Paired Box 3, *PAX7* = Paired Box 7. Structural proteins; *DES*, desmin, *NEB*, nebulin, *TNNT1*, Troponin T1 - Slow Skeletal Type, *TRIM63*, Tripartite Motif Containing 63, *TTN*, titin and MSTN, Myostatin. Transcripts evaluated but not shown included; *EYA1*, *LBX1*, *MEF2B*, *MEOX2*, *MITF*, *MSX1*, *PITX1*, *SIM2*, *SIX1*, *SIX4*, *TFE3* and *TFEB*.](peerj-08-9394-g003){#fig-3}

These data also provide a unique opportunity to assess the potential cell surface phenotype of ASPS-1. [@ref-3] identified 2886 proteins that are known, or are predicted by machine learning, to be expressed on the cell surface . Here, ASPS-1 raw microarray data was filtered for these targets and the list sorted in terms of expression. The resultant ASPS-1 'surfaceome' is shown in [Data S2](#supp-2){ref-type="supplementary-material"}. As could be anticipated, *GPNMB* was the highest expressed mRNA; followed by novel surface makers such as the glutamate transporter *SLC38A1* and the amyloid beta (A4) precursor protein *APP*. In terms of CD antigens, the following mRNAs were highly expressed in ASPS-1; *CD9 (TSPAN29), CD26 (DPP4), CD49C (ITGA3), CD54 (ICAM1), CD63 (TSPAN30), CD68 (SCARD1), CD130 (IL6ST), CD146 (MCAM), CD147 (BSG), CD151 (SFA-1), CD166 (ALCAM), CD222 (IGF2R), CD230 (PRP), CD236 (GPC), CD243 (ABCB1),* and *CD325 (CDHN).*

Many of these observations are also compatible with a mesenchymal stromal cell. For example, CD9 (TSPAN29) and CD243 (ABCB1), although widely expressed, are found to varying degrees on MSC ([@ref-26]; [@ref-32]). CD49C (ITGA3) and CD151 (SFA-1) are both markers of chondrogenic differentiation in MSC ([@ref-18]; [@ref-41]) . Expression of CD54 (ICAM1) can be induced in MSC ([@ref-53]), CD63 (TSPAN30) is expressed by bone marrow MSC ([@ref-43]), CD68 (SCARD1) expression has been shown on MSC from human umbilical cord ([@ref-38]) and CDH2 is a regulator of mesenchymal stem cell fate ([@ref-1]). Exosomes expressing Basigin, BSG (CD147), have been shown to promote angiogenesis in MSC ([@ref-71]). CD147 is also a major constituent of the pre-crystalline granules present in ASPS ([@ref-39]). Expression of Melanoma Cell Adhesion Molecule, MCAM (CD146), mRNA provides strong evidence for an MSC derivation, with several studies demonstrating an important role for this molecule in MSC maintenance and differentiation ([@ref-8]; [@ref-11]; [@ref-28]; [@ref-61]). Likewise, Activated Leukocyte Cell Adhesion Molecule (ALCAM, CD166), is a recognized marker of MSC and implicated in osteogenesis ([@ref-6]; [@ref-24]).

In summary, the results presented here demonstrate that the ASPS-1 transcriptome is unique amongst the NCI sarcoma panel, where the closest relatives are normal mesenchymal cells and connective tissue sarcomas. Although ASPS-1 has an expression signature with some similarity to skeletal/cardiac muscle tissue, markers of myogenesis were not detected in this cell line. Furthermore, the ASPS-1 surfaceome does not immediately speak to a tissue derivation but suggests an undifferentiated mesenchymal state.

The next phase of the project involved re-analyzing microarray and RNA-seq data from ASPS tumor resections. [GSE13433](GSE13433) comprises microarray data (Affymetrix U133 plus 2.0) for seven patients with primary or metastatic ASPS ([@ref-60]). In the original study, universal RNA (representing a collection of adult human tissues) was used as a reference. However, patient samples 1,3, 5 and 6 were obtained from skeletal muscle biopsies whereas samples 4 and 7 were isolated from lung. As a consequence, microarray data from normal skeletal muscle and lung represent more appropriate controls. Therefore, skeletal muscle arrays were obtained from [GSE17070](GSE17070) and normal lung samples from [GSE118370](GSE118370). Patient 2 data, derived from the mandible, was excluded from the analysis for lack of an appropriate control. Two lists of differentially expressed transcripts were then generated for patients 1,3,5,6 vs. skeletal muscle and 4,7 vs. normal lung. Results from these two experiments were largely concordant with the profiles obtained in the original study ([@ref-60]). However, in Stockwin et al. muscle-differentiation associated transcripts ITGB1BP3/MIBP, MYF5 and MYF6 were identified as overexpressed. In our analysis, only MYF6 was identified, and only in the experiment involving patients 4 and 7 vs. normal lung; supporting our inference that the published study over-emphasized myogenic differentiation in patient ASPS.

[GSE32569](GSE32569) is a similar ASPS dataset where U133 plus 2.0 microarrays were generated from patients treated with Cediranib ([@ref-37]). We undertook to use this data to generate a list of differentially expressed transcripts from pre-treatment arrays relative to [GSE17070](GSE17070) skeletal muscle samples. Results again showed a similar profile to that obtained from the analysis of [GSE13433](GSE13433). The final experiment was performed using RNA-seq data from [GSE54729](GSE54729). In this published study, data was generated from five human ASPS tumor samples in order to compare the transcriptome with five mouse tumors generated through ectopic expression of ASPSCR1-TFE3 ([@ref-17]). Here, FKPM values for the five human tumors and three skeletal muscle controls were used to generate a list of differentially expressed transcripts. The top fifty upregulated transcripts generated from each of the four experiments using [GSE13433](GSE13433), [GSE32569](GSE32569) and [GSE54729](GSE54729) are shown in [Table 2](#table-2){ref-type="table"}. Meta-analysis of data from these four *in vivo* studies had considerable overlap, emphasizing the consistent upregulation of mRNAs such as *GPNMB*, *ABCB5*, *PSG9*, *CYP17A1*, *PRL*, *SULT1C2,* and *SV2B*. As with ASPS-1, over-expression of myogenic regulatory factor mRNA was not consistently seen in any of the experiments involving patient samples (results not shown). Lastly, lists of differentially expressed genes from both ASPS-1 and patient sample experiments were combined (at a five-fold cut-off [^2^](#fn-2){ref-type="fn"} [^2]), and a VENN diagram generated in order to determine the extent of overlap ([Fig. 4](#fig-4){ref-type="fig"}). Results demonstrated that twenty-five transcripts were elevated in all of the meta-analyses, whereas seventy-three were expressed at the intersection between all *in vivo* analyses.

10.7717/peerj.9394/table-2

###### The top fifty upregulated transcripts generated from each of the four experiments utilizing ASPS patient data from [GSE13433](GSE13433), [GSE32569](GSE32569) and [GSE54729](GSE54729).
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  **[GSE13433](GSE13433) Patients 1,3,5,6 vs. Skeletal muscle**   **[GSE13433](GSE13433) Patient 4,7 vs. Normal lung**   **[GSE32569](GSE32569) Pre-treatment ASPS vs. Skeletal muscle**   **[GSE54729](GSE54729) Patients vs. Skeletal muscle**                                                                                         
  --------------------------------------------------------------- ------------------------------------------------------ ----------------------------------------------------------------- ------------------------------------------------------- ------- ------------ -------------- ------- -------------- ----------------- -------- --------------
  205502_at                                                       639.7                                                  CYP17A1                                                           207733_x\_at                                            608.6   PSG9         211470_s\_at   573.8   SULT1C2        ENSG00000159871   100.9    LYPD5
  212992_at                                                       531.8                                                  AHNAK2                                                            209594_x\_at                                            601.3   PSG9         205502_at      420.6   CYP17A1        ENSG00000183979   423.1    NPB
  205445_at                                                       434.1                                                  PRL                                                               205445_at                                               572.3   PRL          1554018_at     375.0   GPNMB          ENSG00000198203   237.6    SULT1C2
  240717_at                                                       419.0                                                  ABCB5                                                             205502_at                                               537.1   CYP17A1      205342_s\_at   367.4   SULT1C2        ENSG00000148795   1700.4   CYP17A1
  205342_s\_at                                                    338.7                                                  SULT1C2                                                           1555786_s\_at                                           510.2   LINC00520    210809_s\_at   365.1   POSTN          ENSG00000146678   200.6    IGFBP1
  201850_at                                                       258.8                                                  CAPG                                                              206224_at                                               467.6   CST1         238720_at      351.1   LOC101927057   ENSG00000172179   357.1    PRL
  211470_s\_at                                                    252.9                                                  SULT1C2                                                           223572_at                                               437.6   HHATL        210587_at      341.2   INHBE          ENSG00000169006   142.2    NTSR2
  238720_at                                                       248.1                                                  LOC101927057                                                      240717_at                                               346.4   ABCB5        206214_at      262.4   PLA2G7         ENSG00000101197   113.9    BIRC7
  1554018_at                                                      240.8                                                  GPNMB                                                             208555_x\_at                                            322.5   CST2         212992_at      259.6   AHNAK2         ENSG00000170369   345.4    CST2
  205302_at                                                       207.6                                                  IGFBP1                                                            236972_at                                               277.8   TRIM63       1565162_s\_a   241.7   MGST1          ENSG00000100167   143.8    SEPT3
  204638_at                                                       198.2                                                  ACP5                                                              1553663_a\_at                                           259.2   NPB          229831_at      228.7   CNTN3          ENSG00000204632   396.4    HLA-G
  206899_at                                                       170.8                                                  NTSR2                                                             205302_at                                               255.8   IGFBP1       200832_s\_at   225.4   SCD            ENSG00000146070   147.4    PLA2G7
  210587_at                                                       170.4                                                  INHBE                                                             221051_s\_at                                            200.5   NMRK2        206899_at      168.5   NTSR2          ENSG00000110492   313.0    MDK
  212805_at                                                       157.6                                                  PRUNE2                                                            206239_s\_at                                            192.8   SPINK1       205302_at      159.6   IGFBP1         ENSG00000227925   134.1    LOC101929771
  209875_s\_at                                                    150.3                                                  SPP1                                                              210587_at                                               184.3   INHBE        227180_at      157.3   ELOVL7         ENSG00000170373   455.2    CST1
  1557636_a\_at                                                   145.1                                                  C7orf57                                                           206899_at                                               171.9   NTSR2        219648_at      149.3   MREG           ENSG00000225328   118.5    LINC01594
  210809_s\_at                                                    144.4                                                  POSTN                                                             205551_at                                               169.9   SV2B         210397_at      148.0   DEFB1          ENSG00000118785   260.1    SPP1
  221577_x\_at                                                    134.0                                                  GDF15                                                             219106_s\_at                                            149.9   KLHL41       209875_s\_at   147.2   SPP1           ENSG00000139269   137.6    INHBE
  221008_s\_at                                                    133.2                                                  ETNPPL                                                            206799_at                                               146.3   SCGB1D2      557636_a\_a    145.3   C7orf57        ENSG00000102575   190.9    ACP5
  206214_at                                                       130.1                                                  PLA2G7                                                            229052_at                                               143.1   ANKRD23      205825_at      139.0   PCSK1          ENSG00000185518   114.7    SV2B
  209035_at                                                       122.3                                                  MDK                                                               221008_s\_at                                            142.4   ETNPPL       219073_s\_at   138.2   OSBPL10        ENSG00000205336   129.2    ADGRG1
  202450_s\_at                                                    121.7                                                  CTSK                                                              205342_s\_at                                            125.6   SULT1C2      205343_at      132.8   SULT1C2        ENSG00000185567   246.4    AHNAK2
  200832_s\_at                                                    121.0                                                  SCD                                                               212805_at                                               124.7   PRUNE2       555778_a\_a    127.5   POSTN          ENSG00000136235   2756.8   GPNMB
  212806_at                                                       119.7                                                  PRUNE2                                                            1564758_at                                              115.7   LOC643659    221008_s\_at   126.1   ETNPPL         ENSG00000042493   172.1    CAPG
  230067_at                                                       116.8                                                  FAM124A                                                           229831_at                                               114.5   CNTN3        231736_x\_at   116.1   MGST1          ENSG00000143387   1718.2   CTSK
  208555_x\_at                                                    116.8                                                  CST2                                                              209738_x\_at                                            113.4   PSG6         212805_at      115.1   PRUNE2         ENSG00000030582   707.5    GRN
  225275_at                                                       115.8                                                  EDIL3                                                             233389_at                                               107.5   CFAP61       558378_a\_a    108.4   AHNAK2         ENSG00000107317   354.1    PTGDS
  229831_at                                                       112.1                                                  CNTN3                                                             212992_at                                               106.9   AHNAK2       218292_s\_at   98.4    PRKAG2         ENSG00000106617   161.8    PRKAG2
  227404_s\_at                                                    111.2                                                  EGR1                                                              233238_s\_at                                            106.0   CTB-12O2.1   221577_x\_at   94.6    GDF15          ENSG00000216490   275.5    IFI30
  212841_s\_at                                                    109.4                                                  PPFIBP2                                                           1569072_s\_at                                           102.9   ABCB5        218404_at      94.0    SNX10          ENSG00000183696   183.0    UPP1
  216834_at                                                       108.8                                                  RGS1                                                              206994_at                                               87.9    CST4         233748_x\_at   90.8    PRKAG2         ENSG00000110092   192.1    CCND1
  208792_s\_at                                                    106.1                                                  CLU                                                               239205_s\_at                                            84.7    CR1; CR1L    224918_x\_at   89.1    MGST1          ENSG00000212443   410.2    SNORA53
  223362_s\_at                                                    105.2                                                  SEPT3.                                                            217871_s\_at                                            84.7    MIF          212070_at      86.0    ADGRG1         ENSG00000185585   105.1    OLFML2A
  208791_at                                                       92.7                                                   CLU                                                               226086_at                                               83.8    SYT13        205551_at      85.1    SV2B           ENSG00000130203   285.1    APOE
  1558846_at                                                      92.7                                                   PNLIPRP3                                                          213175_s\_at                                            82.5    SNRPB        244444_at      84.5    PKD1L2         ENSG00000111412   119.3    C12orf49
  230746_s\_at                                                    92.3                                                   N/A                                                               221523_s\_at                                            81.9    RRAGD        208965_s\_at   83.6    IFI16          ENSG00000206503   1571.8   HLA-A
  218292_s\_at                                                    89.1                                                   PRKAG2                                                            243167_at                                               77.0    ABCB5        208146_s\_at   82.8    CPVL           ENSG00000106066   239.3    CPVL
  1565162_s\_at                                                   88.4                                                   MGST1                                                             206372_at                                               74.4    MYF6         226847_at      82.8    FST            ENSG00000138131   108.9    LOXL4
  205825_at                                                       83.7                                                   PCSK1                                                             209875_s\_at                                            70.5    SPP1         223484_at      80.3    C15orf48       ENSG00000118508   104.3    RAB32
  226372_at                                                       82.7                                                   CHST11                                                            244444_at                                               67.3    PKD1L2       234983_at      78.9    C12orf49       ENSG00000174080   454.1    CTSF
  202503_s\_at                                                    82.6                                                   KIAA0101                                                          205862_at                                               65.9    GREB1        240717_at      78.3    ABCB5          ENSG00000169116   207.1    PARM1
  205343_at                                                       82.0                                                   SULT1C2                                                           222379_at                                               65.8    KCNE4        229177_at      78.1    C16orf89       ENSG00000120885   187.0    MIR6843
  205551_at                                                       81.7                                                   SV2B                                                              1554371_at                                              60.2    PKD1L2       205844_at      75.8    VNN1           ENSG00000214435   114.9    AS3MT
  1569072_s\_at                                                   81.5                                                   ABCB5                                                             205825_at                                               58.2    PCSK1        238376_at      75.5    LOC100505564   ENSG00000130208   134.3    APOC1
  227180_at                                                       79.8                                                   ELOVL7                                                            222714_s\_at                                            55.6    LACTB2       205445_at      73.0    PRL            ENSG00000100644   335.4    HIF1A
  231736_x\_at                                                    79.5                                                   MGST1                                                             218619_s\_at                                            54.6    SUV39H1      242340_at      71.7    N/A            ENSG00000135047   458.4    CTSL
  202037_s\_at                                                    76.5                                                   SFRP1                                                             236523_at                                               54.3    LOC285556    204285_s\_at   71.3    PMAIP1         ENSG00000144136   134.6    SLC20A1
  219648_at                                                       74.5                                                   MREG                                                              1557636_a\_at                                           53.7    C7orf57      204466_s\_at   71.3    SNCA           ENSG00000101846   109.4    STS
  206685_at                                                       71.8                                                   HCG4                                                              212070_at                                               52.9    ADGRG1       203767_s\_at   70.7    STS            ENSG00000111775   242.3    COX6A1
  210397_at                                                       71.0                                                   DEFB1                                                             204830_x\_at                                            52.8    PSG5         222872_x\_at   70.5    NABP1          ENSG00000089101   164.4    CFAP61

An exploration of the twenty-five conserved transcripts in the context of stem cell biology provides further insights into MSC lineage potential. For example; angiopoietin Like 2 (ANGPTL2) is a regulator of stem cell adipogenesis, chondrogenesis and osteogenesis ([@ref-63]; [@ref-67]). Expression of Cathepsin K (CTSK) is compelling given that in mice CTSK-mGFP cells label the periosteal mesenchyme and have been used to identify periosteal stem cells ([@ref-9]). As previously noted, Dipeptidyl Peptidase 4 (DPP4), also known as CD26, marks mesenchymal preadipocyte progenitors ([@ref-44]). Glycoprotein Nmb (GPNMB) should be recognized as the prototypic cell surface marker for ASPS. As stated, GPNMB is recognized as a marker of mesenchymal cells ([@ref-35]). Interestingly, within protein atlas, the cell line designated 'ASC diff', a differentiated adipose-derived mesenchymal stem cell line has the highest expression of GPNMB and also expresses *TRIM63, CRYAB, FABP3, and CTSK.* These observations would appear to favor the concept that ASPS resembles an MSC capable of adipogenic, chondrogenic or osteogenic differentiation.

Several inferences can also be made for the seventy-three conserved transcripts identified in all ASPS patient experiments. The multi-drug resistance transporter ABCB5, in addition to being expressed by melanoma, also defines a subset of MSC in the cornea and skin ([@ref-14]; [@ref-34]; [@ref-70]). The hormone prolactin (PRL) has been shown to stimulate proliferation of MSC and also to direct chondrogenic and ostegenic differentiation ([@ref-48]; [@ref-59]; [@ref-62]). Increased expression of the growth factor midkine (MDK) has been noted in previous ASPS gene expression studies and is an MSC survival factor ([@ref-60]; [@ref-75]). Upregulation of hypoxia-related transcripts such as HIF1A suggests that this pathway is active in ASPS and, although ubiquitous, HIF1A plays an important role in the control of multipotency for MSC ([@ref-49]). It was similarly interesting that the ASPS patient experiments showed increased expression of *THY1* (CD90) relative to control samples. This target is regarded as a classical marker of MSC and has recently been shown to promote osteogenic differentiation over an adipogenic fate ([@ref-55]). In summary, re-analysis of microarray and RNA-seq data for ASPS patient samples yielded transcriptomes with considerable overlap between studies irrespective of platform technology; and the final consensus ASPS transcriptome resembles an undifferentiated mesenchymal stromal cell.

![VENN diagram showing overlap between analyses.\
Lists of over-expressed transcripts (five-fold cut off) were used to determine extent of overlap between the five datasets. The number of differentially expressed transcripts at five-fold is underlined. Callouts show the 25 transcripts over-expressed in all experiments and the 73 found in all ASPS patient analyses.](peerj-08-9394-g004){#fig-4}

Conclusions
===========

Alveolar-soft part sarcoma is an example of a malignancy that has, despite several immunohistochemical and genomics studies, evaded classification ([@ref-12]; [@ref-13]; [@ref-16]; [@ref-17]; [@ref-23]; [@ref-46]; [@ref-58]; [@ref-60]; [@ref-64]; [@ref-66]; [@ref-72]). This study was prompted by the public release of exon expression data for the cell line ASPS-1, which offers a unique opportunity to study ASPS in isolation ([@ref-31]; [@ref-68]). We were similarly interested in revisiting the genomic studies of ourselves and others to generate a consensus expression profile independent of platform technology.

The central finding of the current study was that the ASPS transcriptome is indicative of an undifferentiated mesenchymal stromal cell (MSC). Specifically, The ASPS-1 cell line exhibited a mesenchymal expression signature, where expression data clustered with normal and malignant mesenchymal cells within the NCI sarcoma cell line panel. The ASPS-1 surfaceome was similarly suggestive of an undifferentiated mesenchymal cell. Generation of an ASPS consensus transcriptome from previously reported patient studies highlighted the importance of targets such as *GPNMB*, ABCB5, *CSTK*, *DPP4*, *BSG*, *ALCAM, PRL,* and *CDHN;* all of which were consistent with an undifferentiated MSC. Conversely, the ASPS transcriptome lacked expression of myogenesis-related genes and did not feature transcripts indicative of neural, pericyte or endothelial differentiation.

MSC are found in most tissues, these cells are capable of multipotent differentiation into bone, muscle, cartilage, adipocytes, marrow stromal cells, tenocytes, fibroblasts, endothelial and neural cells ([@ref-7]; [@ref-51]). Tissues maintain a pool of MSC, with varying degrees of specialization, ready to dynamically replenish differentiated cells in response to signals associated with growth, homeostasis or damage ([@ref-54]). Prior to this study, ASPL-TFE3 had already been shown to immortalize embryonic mesenchymal cells ([@ref-66]). The suggestion that ASPS resembles a mesenchymal stromal progenitor provides a plausible explanation for the failure of previous studies to pinpoint cellular origin, given that the cell retains an undifferentiated state. Evidence from this study favors an MSC capable of adipogenic, osteogenic or chondrogenic differentiation, but not necessarily at the exclusion of other lineages.

If an MSC origin for ASPS could ultimately be confirmed, there would be important consequences for therapeutic development. Foremost is the suggestion that ASPS growth may be inhibited by factors that promote MSC differentiation. For example, several high-throughput studies have identified clinically relevant small molecules capable of promoting or inhibiting differentiation of MSC ([@ref-5]; [@ref-25]). Re-screening these compounds for their ability to inhibit the growth of ASPS-1 may yield clinically tractable candidates for ASPS treatment. From the authors perspective, the effect of HDAC inhibitors, steroids and retinoids on ASPS-1 growth are of particular interest ([@ref-42]; [@ref-56]).

The findings of this study have a central caveat; all speculation regarding cellular origin must be moderated until the inference of ASPL-TFE3 is removed. Given the ability of this fusion protein to re-direct transcription, the observed transcriptomes may mask the true cellular origin. For example, *GPNMB*, *CRYAB, CYP17A1, SULT1C2, UPP1* and *SV2B* have been shown to be up-regulated following expression of ASPL-TFE3 in inducible 293 cells ([@ref-33]). Therefore, the current study only suggests that ASPS resembles an MSC and no firm conclusion can be made regarding origin. A straightforward approach to address this central question involves generating an ASPL-TFE3 knockout in ASPS-1 perhaps with re-introduction of wild-type TFE3 to maintain viability. The resultant line could then be characterized by RNA-seq and FACS phenotyping. These experiments could be accompanied by the addition of defined media to determine whether differentiation can be directed toward specific MSC lineages. In the interim, the data presented here provides a unified picture of ASPS mRNA expression, where considerable similarity with mesenchymal stromal progenitors is evident.
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